ACON: Aclarion, Inc. EV/EBITDA Multiple

Aclarion (ACON) delegates cloud infrastructure support to external IT partners to focus on refining its neural network algorithms. However, current license pricing is constrained by insurance providers' requirements for proof of the software's economic efficiency. The price indicator on the GURU.Markets platform chart, which stands at 0.00, complements the profile of this innovator, which has developed a unique method for objectively identifying the source of spinal pain via MRI analysis.

Aclarion Corporation - ACON Enterprise Value to EBITDA Ratio (period 11/23/2025 - 11/10/2026)

Summary analytical data breakdowns for aclarion.com (ACON)

- stock price and consensus target price:

Stock Quotes Aclarion Corp|ACON - Analyst Forecast Prices

- market capitalization information:

Market Capitalization Aclarion Corporation|ACON - Company Buyout Price

- issuer book value statistics:

Book Value per Share Aclarion|ACON - Company Net Assets|Market Cap to Net Assets Ratio aclarion.com|ACON - Aggregate Asset Value

- company liabilities and liquidity data:

- financial results and valuation multiples details:

ACON - Net Income|Projected Future Earnings Aclarion|ACON - P/E Multiple|Future Price to Earnings Aclarion|ACON - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Aclarion Corporation|ACON - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Aclarion|ACON - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months aclarion.com|ACON - Net earnings per share change in current year|Expected earnings per share growth for next year Aclarion

Initial company analysis:Aclarion Corp ACON

Scaling the Nociscan AI platform across US clinics requires precise monitoring of the cost of capital relative to operational efficiency. By analyzing the EV/EBITDA ratio of Aclarion (ACON) over a time series, an investor compares the total market price of the business, including debt, with earnings before interest, taxes, depreciation, and amortization. A decrease in this multiple confirms the asset is undervalued, whereas a sharp increase signals that it is overbought or that profitability is declining.

Competitor analysis for Aclarion

Abbott Laboratories Inc. - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio TMO (Thermo Scientific)|GE HealthCare - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio mt.com MTD|WAT: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Bio-Techne Corp|Enterprise Value to EBITDA Ratio BRKR|AZTA: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Varex Imaging (VREX)|Enterprise Value to EBITDA Ratio semlerscientific.com SMLR|EV/EBITDA Multiple BFLY (Butterfly Network)|Mesa Laboratories Inc (MLAB) - Company Value to EBITDA|Quantum-Si Corp - EV/EBITDA Multiple|NNOX (Nano-X Imaging Ltd) - Enterprise Value to Operating Income Before Depreciation|QTRX: EV/EBITDA Multiple|MASS - Total Company Value to Operating Income Before Depreciation Ratio|CV (CapsoVision, Inc.) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio MaxCyte Inc. (MXCT)|EV/EBITDA Multiple RPID|EV/EBITDA Multiple Seer Bio (SEER)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Hyperfine, Inc. HYPR|fonar.com - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|DXR: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation MDAI (spectral-ai.com)|VIVS: EV/EBITDA Multiple|Company Value to EBITDA Akoya Biosciences, Inc. (AKYA)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ThermoGenesis|TLIS - Enterprise Value to EBITDA Multiple|Enterprise Value to EBITDA Ratio TTOO (T2 Biosystems)